Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Giles

Leukemia

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Leukemia|May 29, 2009
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaF J Giles, M O'Dwyer, R Swords
Leukemia|September 30, 2005
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cellsR-H Xu, H Pelicano, H Zhang, et al.
Leukemia|December 1, 2006
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphomaT Haritunians, A Mori, J O'Kelly, et al.
Leukemia|May 1, 1992
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cellsA P Jewell, K L Yong, C P Worman, et al.
Leukemia|August 22, 2003
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromesS Yazji, F J Giles, A-M Tsimberidou, et al.
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
Leukemia|May 15, 2007
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1J Pan, A Quintás-Cardama, T Manshouri, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Leukemia|March 6, 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisF J Giles, M J Mauro, F Hong, et al.
Leukemia|July 29, 2005
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemiasH M Amin, Y Yang, Y Shen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Leukemia|May 29, 2009
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaF J Giles, M O'Dwyer, R Swords
Leukemia|September 30, 2005
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cellsR-H Xu, H Pelicano, H Zhang, et al.
Leukemia|December 1, 2006
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphomaT Haritunians, A Mori, J O'Kelly, et al.
Leukemia|May 1, 1992
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cellsA P Jewell, K L Yong, C P Worman, et al.
Leukemia|August 22, 2003
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromesS Yazji, F J Giles, A-M Tsimberidou, et al.
Leukemia|April 4, 2008
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismH Zhang, D Trachootham, W Lu, et al.
Leukemia|May 15, 2007
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1J Pan, A Quintás-Cardama, T Manshouri, et al.
Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.
Leukemia|March 6, 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisF J Giles, M J Mauro, F Hong, et al.
Leukemia|July 29, 2005
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemiasH M Amin, Y Yang, Y Shen, et al.
Pageof 3